Subscribe
Trials of aliskiren for CAD and otamixaban for NSTE-ACS, chronic care management for substance dependence, and more.

JAMA Editor’s Summary

Trials of aliskiren for CAD and otamixaban for NSTE-ACS, chronic care management for substance dependence, and more.

Editor's Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the September 18, 2013 issue
September 17, 2013

Trials of aliskiren for CAD and otamixaban for NSTE-ACS, chronic care management for substance dependence, and more.

Editor’s Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the September 18, 2013 issue

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
Cultivating Resilience During Times of Crisis and Existential Threat Keith interviews Dr. Chris Recinos, the CEO and founder of Nurse Leader Network, regarding mental health, adaptive and maladaptive mechanisms of resilience, and conscious self-development.